Back to All

Stefan McDonald joins Diaceutics EXCO team as Chief Growth Officer

1 November, 2021

Diaceutics are pleased to announce that Stefan McDonald has been promoted to Chief Growth Officer and will serve on the EXCO team. In his new role Stefan will provide leadership to drive organisation wide growth with a focus on further development of the DXRX platform, expansion of the Global lab Network, Tech enabled and Implementation services. As Chief Growth Officer, Stefan will work cross functionally to promote operational efficiency and cohesion within the organisation, acting as a catalyst to drive cultural and organisational change. 

Stefan has been with Diaceutics since 2020, coming from Optum (US Health Services & Innovation company) having served as a Pharmacist, Business and Product lead and a key member of their Senior Leadership team. Stefan joined as Head of the Labs Team and has been instrumental in the launch of DXRX – The Diagnostic Network® the world’s first diagnostic commercialization platform for Precision Medicine, integrating multiple pipelines of real-world diagnostic testing data from Diaceutics global network of laboratories.  

“Diaceutics is a unique leader in Precision Medicine, with a distinct value proposition. I believe that by leveraging our Real-World Evidence, using the deep understanding of our continually growing global lab network and coupling this with our use of technology via our DXRX platform, we can continue to grow at pace, while improving our ability to better serve our clients” said Stefan. 

“As an example, our DXRX Patient Mapping Solution enables longitudinal analysis of biomarker testing and the overall testing journey of individual patients to provide a deeper understanding of the commonalities, variances and essential insights necessary to support decisions and drive successful commercialisation of testing, Diaceutics is breaking down the barriers to testing to drive better patient treatment’ explains Stefan. 

 Commenting on Stefan’s new role as Chief Growth Officer, CEO of Diaceutics Peter Keeling said, “Stefan has displayed consistent business acumen, admirable leadership skills, and a hunger for our vision, all the while demonstrating strong cultural values that are aligned with us at Diaceutics.” 

As part of his role as Chief Growth Officer, Stefan hopes to continue to invest in the right talent and people who share the same vision of ‘Better Testing, Better Treatment’ and to further drive the success and growth of Diaceutics. He added, "Value and Culture are key; they are as important internally on how we work together, as they are externally in how we work and collaborate with our partners and clients who share our values. It drives and motivates our work – to do the right thing, and to go above and beyond knowing there is an anchor in person centred outcome.” 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny